Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL

Overview of attention for article published in Frontiers in Pharmacology, August 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (54th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 6,159 followers.

RT @FrontPharmacol: New Research: Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL #pharmacology ht…

New Research: Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL #pharmacology https://t.co/Gn6FL2BT22

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.